ProShare Advisors
NGM

ProShare Advisors’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

ProShare Advisors’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-11,069
Closed -$11.8K – 1979
2023
Q3 		$11.8K Buy
11,069
+72
+0.7% +$149 ﹤0.01% 1802
2023
Q2 		$28.5K Buy
10,997
+550
+5% +$1.96K ﹤0.01% 1818
2023
Q1 		$42.6K Sell
10,447
-1,514
-13% -$7K ﹤0.01% 1684
2022
Q4 		$60K Buy
11,961
+823
+7% +$5.16K ﹤0.01% 1720
2022
Q3 		$145K Buy
11,138
+562
+5% +$8.51K ﹤0.01% 1473
2022
Q2 		$136K Sell
10,576
-3,373
-24% -$46.7K ﹤0.01% 1556
2022
Q1 		$213K Sell
13,949
-3,881
-22% -$60.5K ﹤0.01% 1851
2021
Q4 		$316K Sell
17,830
-2,732
-13% -$52.4K ﹤0.01% 1754
2021
Q3 		$432K Sell
20,562
-1,450
-7% -$31.9K ﹤0.01% 1298
2021
Q2 		$434K Buy
22,012
+4,962
+29% +$116K ﹤0.01% 1632
2021
Q1 		$496K Buy
17,050
+1,119
+7% +$31.3K ﹤0.01% 1445
2020
Q4 		$483K Buy
15,931
+1,918
+14% +$42K ﹤0.01% 1298
2020
Q3 		$223K Sell
14,013
-68
-0.5% -$1.24K ﹤0.01% 1360
2020
Q2 		$278K Buy
14,081
+3,470
+33% +$66.3K ﹤0.01% 1268
2020
Q1 		$131K Sell
10,611
-7,112
-40% -$116K ﹤0.01% 1054
2019
Q4 		$328K Buy
+17,723
New +$259K ﹤0.01% 1284

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ProShare Advisors's NGM Position: Q4 2023 in Review

ProShare Advisors sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q4 2023, closing a stake of 11,069 shares — an estimated $11.8K sold.

ProShare Advisors first reported a position in NGM in Q4 2019 and held it in 16 quarters. The position peaked at $496K in Q1 2021. 83 funds tracked by Wall St. Rank hold NGM as of Q4 2023.

  • ProShare Advisors reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • ProShare Advisors sold 11,069 NGM Biopharmaceuticals, Inc. Common Stock shares in Q4 2023, an estimated $11.8K.
  • ProShare Advisors first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 16 quarters.
  • ProShare Advisors's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $496K in Q1 2021.
  • 83 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q4 2023.

Based on ProShare Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.